オーリニア・ファーマシューティカルズ
Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | 0.26 | $78M | $33M |
| 2025 Q4 | 1.58 | $77M | $45M |
| 2025 Q3 | 0.24 | $73M | $44M |
| 2025 Q2 | 0.16 | $70M | $44M |
| 2025 Q1 | 0.16 | $62M | $1M |
| 2024 Q4 | 0.01 | $60M | $30M |
| 2024 Q3 |
| 0.10 |
| $68M |
| $17M |
| 2024 Q2 | 0.01 | $57M | $16M |